magnifying glass
logo for Axcella

Axcella

Manufacturing · Massachusetts, United States · 64 Employees

Get Full Access

Who is Axcella

Axcella Health formerly known as Pronutria biotechnology company focuses on research and development of novel multifactorial interventions to support health andaddress dysregulated metabolism across a broad spectrum of consumers, and patients who have limited options.Read More

Headquarters

Headquarters:

840 Memorial Drive Third Floor, Cambridge, Massachusetts, 02139, United States
Phone Number

Phone Number:

(617) 868-0949
Revenue

Revenue:

$13 Million
Stock Symbol

Stock Symbol:

AXLA
Axcella's Social Media
SIC Code 28,283
NAICS Code 32541,325
Ticker NASDAQ: AXLA
Popular Searches:

Axcella Health Inc

axcella health inc.

Axcella

Axcella Health

Axcella Health, Inc.

Top Competitors of Axcella

Employess
66
revenue
$22 Million

1

Employess
<25
revenue
<$5 Million

2

Employess
50
revenue
<$5 Million

3

Employess
26
revenue
$8 Million

4

Employess
28
revenue
$5 Million

5

Employess
51
revenue
<$5 Million

6

Axcella's Org Chart

William Hinshaw
William Hinshaw

President & Chief Executive Officer

PhonePhoneEmailEmail
Ewa Tam
Ewa Tam

Product Commercialization Chief of ...

PhonePhoneEmailEmail
Andrew Suchoff
Andrew Suchoff

Senior Vice President and Chief Peo...

PhonePhoneEmailEmail

PhonePhoneEmailEmail
Illustration of an envelope

Axcella Company Metrics

Company Insights
Employee Growth Rate
Funding
Funding DateRoundAmountInvestors

May 13, 2019

Stock Issuance/Offering

$71M

-

Nov 22, 2018

Series E

$59M

-

Feb 23, 2016

Series D

$42M

Nestlé Health Science

See More

$234M

Total Funding Amount

$71M

Most Recent Funding Amount

6

Number of Funding Rounds

Revenue
QuarterRevenue

'21 - Q1

13526000

'21 - Q2

13526000

Axcella News & Media

Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today reported topline results from the Phase 2a randomized, double-blind, placebo-controlled investigation to evaluate the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID. Long COVID is a persistent and growing challenge of the

Great news for Axcella Health Inc. (NASDAQ:AXLA): Insiders acquired stock in large numbers last year

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it has prioritized its clinical development portfolio after rapid enrollment for its Phase 2a clinical trial in Long COVID. The company affirmed topline data readout for its Phase 2a Long COVID trial in early Q3 2022 and interim data readout f
Subscribe to "Axcella" News

Frequently Asked Questions regarding Axcella

Where are Axcella’s headquarters?

Axcella’s headquarters are in 840 Memorial Drive Third Floor, Cambridge, Massachusetts, 02139, United States

What is Axcella’s phone number?

Axcella’s phone number is (617) 868-0949

What is Axcella’s stock symbol?

Axcella’s stock symbol is AXLA

What is Axcella’s official website?

Axcella’s official website is www.axcellahealth.com

What is Axcella’s Revenue?

Axcella’s revenue is $13 Million

What is Axcella’s SIC code?

Axcella’s SIC: 28,283

What is Axcella’s NAICS code?

Axcella’s NAICS: 32541,325

How many employees are working in Axcella?

Axcella has 64 employees

What is Axcella’s industry?

Axcella is in the industry of: Manufacturing, Pharmaceuticals, Business Services

Who are Axcella’s main competitors?

Axcella's main competitors are: BiomX, Cleveland Biolabs, GlycoMimetics, Galera Therapeutics

What is Axcella's tech stack?

The technologies that are used by Axcella are: R, Python, PHP, DocuSign

Who is Axcella's CEO?

Axcella's CEO is William Hinshaw

See more information about Axcella
4.4/5 on G2 Crowd